Paul Manning Biography and Net Worth

Director of Liquidia

Mr. Manning is the President and CEO of PBM Capital Group based in Charlottesville, VA. An entrepreneur with thirty years of experience in the healthcare industry, Mr. Manning founded PBM Capital Group in 2010, a private equity investment firm in the business of investing in health care and life-science related companies. Mr. Manning directs all investment decisions and sits on the board of directors for many of PBM Capital’s investments including: Avexis (NASDAQ:AVXS), Dova Pharmaceuticals, Verrica Pharmaceuticals, and PBM Pharmaceuticals. Mr. Manning has successfully founded several companies that developed and distributed prescription and over the counter products to major chains in the United States. In 1997, Mr. Manning founded PBM Products, which became the largest private label producer of infant formula and baby/toddler food in the world. PBM Products was sold to Perrigo Corporation in 2010. Mr. Manning served on Perrigo Corporation’s Board of Directors after the sale. Mr. Manning is an active member of the University of Virginia community, having served on the Board of UVA Strategic Planning Committee, the Board of UVA Health Foundation, and the Board of the President’s Advisory Committee. Mr. Manning graduated from the University of Massachusetts with a B.S. in Microbiology. Mr. Manning was named Virginia Entrepreneur of the Year by Ernst and Young in 2002.

What is Paul B. Manning's net worth?: The estimated net worth of Paul B. Manning is at least $14.47 million as of December 16th, 2024. Mr. Manning owns 1,303,752 shares of Liquidia stock worth more than $14,471,647 as of December 22nd. This net worth estimate does not reflect any other investments that Mr. Manning may own. Learn More about Paul B. Manning's net worth.
How do I contact Paul B. Manning?: The corporate mailing address for Mr. Manning and other Liquidia executives is 419 DAVIS DRIVE SUITE 100, MORRISVILLE NC, 27560. Liquidia can also be reached via phone at (919) 328-4400 and via email at [email protected]. Learn More on Paul B. Manning's contact information.
Has Paul B. Manning been buying or selling shares of Liquidia?: Paul B. Manning has not been actively trading shares of Liquidia in the last ninety days. Most recently, on Tuesday, April 13th, Paul B. Manning bought 198,413 shares of Liquidia stock. The stock was acquired at an average cost of $2.52 per share, with a total value of $500,000.76. Following the completion of the transaction, the director now directly owns 111,706 shares of the company's stock, valued at $281,499.12. Learn More on Paul B. Manning's trading history.
Who are Liquidia's active insiders?: Liquidia's insider roster includes Arthur Kirsch (Director), Paul Manning (Director), and Russell Schundler (General Counsel). Learn More on Liquidia's active insiders.
Are insiders buying or selling shares of Liquidia?: In the last year, Liquidia insiders bought shares 1 times. They purchased a total of 150,000 shares worth more than $1,426,500.00. In the last year, insiders at the sold shares 30 times. They sold a total of 116,687 shares worth more than $1,636,090.52. The most recent insider tranaction occured on December, 2nd when insider Scott Moomaw sold 546 shares worth more than $6,284.46. Insiders at Liquidia own 30.1% of the company. Learn More about insider trades at Liquidia.
Information on this page was last updated on 12/2/2024.

Paul B. Manning Insider Trading History at Liquidia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/13/2021	Buy	198,413	$2.52	$500,000.76	111,706

Paul B. Manning Buying and Selling Activity at Liquidia

Liquidia Company Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Today's Range

Now: $11.10

$10.51

$11.22

50 Day Range

MA: $10.91

$9.82

$11.63

2 Week Range

Now: $11.10

$8.26

$16.99

Volume

2,698,847 shs

Average Volume

971,806 shs

Market Capitalization

$939.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.22

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.